<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329001</url>
  </required_header>
  <id_info>
    <org_study_id>213362</org_study_id>
    <secondary_id>3000-01-004</secondary_id>
    <nct_id>NCT03329001</nct_id>
  </id_info>
  <brief_title>Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule</brief_title>
  <official_title>An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a three stage, open label, randomized-sequence, single-crossover Phase 1 study to&#xD;
      evaluate the relative bioavailability (BA) and Bioequivalence (BE) of niraparib administered&#xD;
      as a tablet formulation compared to the reference capsule formulation currently marketed in&#xD;
      the United States. Stage 3 evaluates the effect of a high-fat meal on niraparib&#xD;
      pharmacokinetics (PK) following a single dose of the tablet. The Extension Phase of this&#xD;
      study is to enable participants enrolled in the study to continue to receive treatment with&#xD;
      niraparib tablets if they are tolerating it and, in the Investigator's opinion, may receive&#xD;
      benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">June 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC[0-t]) for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC[0 to inf]) for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax) for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (T1/2) for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal volume of distribution for niraparib-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from administration of the dose to the first quantifiable concentration (Tlag) for niraparib-Stage 3 PK Phase</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events (TEAEs), serious TEAEs and discontinuations due to TEAEs-Stages 1, 2 and 3 PK Phase</measure>
    <time_frame>Up to 54 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs, serious TEAEs and discontinuations due to TEAEs-Extension Phase</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Stage 1: Tablet-Capsule Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Capsule-Tablet Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Tablet-Capsule Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Capsule-Tablet Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: High fat meal-fasted sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: Fasted-high fat meal sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib Tablet</intervention_name>
    <description>Niraparib tablet formulation</description>
    <arm_group_label>Stage 1: Capsule-Tablet Sequence</arm_group_label>
    <arm_group_label>Stage 1: Tablet-Capsule Sequence</arm_group_label>
    <arm_group_label>Stage 2: Capsule-Tablet Sequence</arm_group_label>
    <arm_group_label>Stage 2: Tablet-Capsule Sequence</arm_group_label>
    <arm_group_label>Stage 3: Fasted-high fat meal sequence</arm_group_label>
    <arm_group_label>Stage 3: High fat meal-fasted sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib Capsule</intervention_name>
    <description>Niraparib capsule formulation</description>
    <arm_group_label>Stage 1: Capsule-Tablet Sequence</arm_group_label>
    <arm_group_label>Stage 1: Tablet-Capsule Sequence</arm_group_label>
    <arm_group_label>Stage 2: Capsule-Tablet Sequence</arm_group_label>
    <arm_group_label>Stage 2: Tablet-Capsule Sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
        PK Phase: To be considered eligible to participate in this study, all of the following&#xD;
        requirements must be met:&#xD;
&#xD;
          -  Participants with histologically or cytologically confirmed diagnosis of metastatic or&#xD;
             locally advanced solid tumors that have failed to respond to standard therapy, has&#xD;
             progressed despite standard therapy, or for which no standard therapy exists, and who&#xD;
             may benefit from treatment with a poly (adenosine diphosphate-ribose) polymerase&#xD;
             (PARP) inhibitor as assessed by the Investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          -  Adequate organ function as defined: Absolute neutrophil count ≥ 1,500 per microliter&#xD;
             (/μL) (For Stage 3: &gt;=1000/μL); Platelets ≥ 100,000/μL; Hemoglobin ≥ 9 grams per&#xD;
             deciliter (g/dL) (5.6 millimolar [mM]); Serum creatinine ≤ 1.5 × the upper limit of&#xD;
             normal (ULN) or a calculated creatinine clearance ≥ 60 milliliters per minute (mL/min)&#xD;
             using the Cockcroft-Gault equation or 24-hour urine creatinine clearance.; Total&#xD;
             bilirubin ≤ 1.5 × ULN except in participants with Gilbert's syndrome. Participants&#xD;
             with Gilbert's syndrome may enroll if direct bilirubin ≤ 1.5 × ULN of the direct&#xD;
             bilirubin; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×&#xD;
             ULN unless liver metastases are present, in which case, they must be ≤ 5 × ULN.&#xD;
&#xD;
          -  Participant has recovered to Grade 1 toxicity from prior cancer therapy (a participant&#xD;
             with Grade 2 neuropathy or Grade 2 alopecia is an exception to this criterion and may&#xD;
             qualify for this study).&#xD;
&#xD;
          -  Female participant of childbearing potential is not breastfeeding, has a negative&#xD;
             serum pregnancy test within 72 hours prior to taking study drug and agrees to abstain&#xD;
             from activities that could result in pregnancy from Screening through 180 days after&#xD;
             the last dose of study drug.&#xD;
&#xD;
          -  Male participant agrees to use an adequate method of contraception and not donate&#xD;
             sperm starting with the first dose of study drug through 90 days after the last dose&#xD;
             of study drug.&#xD;
&#xD;
          -  (For Stage 3): CNS inclusion - Based on screening brain magnetic resonance imaging&#xD;
             indicating no evidence of brain metastasis or needing immediate local therapy.&#xD;
&#xD;
          -  Participant is able to eat a high fat meal.&#xD;
&#xD;
          -  Participant is able to fast for a minimum of 10 hours before start of visit and for an&#xD;
             additional 4 hours after study visit.&#xD;
&#xD;
        Extension Phase:&#xD;
&#xD;
          -  ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Adequate organ function as defined: Absolute neutrophil count ≥ 1,500/μL (For Stage 3:&#xD;
             &gt;=1000/μL); Platelets ≥ 100,000/μL; Hemoglobin ≥ 9 g/dL (5.6 mM); serum creatinine ≤&#xD;
             1.5 × the ULN or a calculated creatinine clearance ≥ 60 mL/min (For Stage 3: ≥ 30&#xD;
             mL/min) using the Cockcroft-Gault equation or 24-hour urine creatinine clearance;&#xD;
             Total bilirubin ≤ 1.5 × ULN except in participant with Gilbert's syndrome.&#xD;
             Participants with Gilbert's syndrome may enroll if direct bilirubin ≤ 1.5 × ULN of the&#xD;
             direct bilirubin; AST and ALT ≤ 2.5 × ULN unless liver metastases are present, in&#xD;
             which case, they must be ≤5 × ULN&#xD;
&#xD;
          -  Female participant of childbearing potential is not breastfeeding, has a negative&#xD;
             serum pregnancy test within 72 hours prior to taking study drug and agrees to abstain&#xD;
             from activities that could result in pregnancy from Screening through 180 days after&#xD;
             the last dose of study drug.&#xD;
&#xD;
          -  Male participant agrees to use an adequate method of contraception and not donate&#xD;
             sperm starting with the first dose of study drug through 90 days after the last dose&#xD;
             of study drug.&#xD;
&#xD;
        Key Exclusion Criteria: PK Phase:&#xD;
&#xD;
          -  Known diagnosis of immunodeficiency&#xD;
&#xD;
          -  Symptomatic uncontrolled brain or leptomeningeal metastases.&#xD;
&#xD;
          -  Major surgery within 3 weeks of starting the study or participant has not recovered&#xD;
             from any effects of any major surgery.&#xD;
&#xD;
          -  Participant is considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder; nonmalignant systemic disease; or active, uncontrolled infection.&#xD;
&#xD;
          -  Known history of myelodysplastic syndrome or acute myeloid leukemia.&#xD;
&#xD;
          -  Participant is currently taking any of the following P-glycoprotein (P-gp) inhibitors:&#xD;
             amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan,&#xD;
             cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole,&#xD;
             ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, ticagrelor,&#xD;
             and verapamil (Does not apply for Extension Phase).&#xD;
&#xD;
          -  Participant taking proton pump inhibitors, antacids, or histamine 2 blockers within 48&#xD;
             hours prior to study drug administration (Does not apply for Extension Phase).&#xD;
&#xD;
          -  Participant has gastric, gastro-esophageal or esophageal cancer; participant is unable&#xD;
             to swallow orally administered medication; or participant has gastrointestinal&#xD;
             disorders or significant gastrointestinal resection likely to interfere with the&#xD;
             absorption of niraparib.&#xD;
&#xD;
          -  Participant has known active hepatic disease&#xD;
&#xD;
          -  Participant has a past or current history of chronic alcohol use.&#xD;
&#xD;
          -  Participant has significant pleural effusion or ascites that is expected to require&#xD;
             drainage during the PK Phase (Does not apply for Extension Phase).&#xD;
&#xD;
          -  For Stage 3 only: Participant is currently taking a lipase inhibitor or cholesterol&#xD;
             absorption inhibitor, such as orlistat or ezetimibe, respectively. (Does not apply for&#xD;
             participation in Extension Phase of this study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto Bessudo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto Bessudo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Navid Hafez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Harvey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manish Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Debra L. Richardson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Minal Barve</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amita Patnaik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibitor</keyword>
  <keyword>niraparib</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Zejula</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

